Table 5.

Exposure to rufinamide and risk of CNS adverse events: meta-analysis of headache

Study characteristics			Rufinamide		Placebo		Risk ratio	Weight
Study number	Authors	Year	Events	Total	Events	Total	M-H, Fixed, 95% CI	%
1	Biton et al. [11]	2011	29	176	23	180	1.29 [0.78, 2.14]	21
2	Brodie et al. [10]	2009	59	156	38	157	1.56 [1.11, 2.20]	35
3	Elger et al. [14]	2010	69	262	32	133	1.09 [0.76, 1.57]	39.3
4	Palhagen et al. [15]	2001	3	25	5	25	0.60 [0.16, 2.25]	4.6
Total events			160	619	98	495	1.28 [1.02, 1.59]	100

Heterogeneity: χ = 3.29, d.f. = 3 (P = 0.35); I² = 9%. Test for overall effect: Z = 2.18 (P = 0.03).